Optimi Health Takes MDMA Therapy Into Phase 3 in Canada

Optimi Health Corp. (NASDAQ: OPTH) said on Sept. 16, 2026 that it plans to expand its clinical program with a Health Canada-authorized Phase 3 trial testing the efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers.

Optimi Health Corp. (NASDAQ: OPTH), the Vancouver-based maker of regulated psychedelic drug products, said it plans to expand its clinical program with a Phase 3 trial of MDMA-assisted therapy for post-traumatic stress disorder. The trial has been authorized by Health Canada and will evaluate the efficacy and safety of two MDMA-assisted therapy sessions in up to 100 veterans and frontline workers, the company said in an announcement dated Sept. 16, 2026.

The announcement, carried by Financial Post, describes Optimi as a commercial-stage pharmaceutical manufacturer. That distinction matters for how investors should read the news: the company already produces regulated psychedelic drug products, and the trial pushes it further up the value chain, from supplying material to generating clinical evidence of its own.

A manufacturer stepping into late-stage clinical work

Most companies in the psychedelic therapeutics field started as drug developers and had to solve manufacturing later. Optimi's path runs the other way. It describes itself as commercial-stage on the manufacturing side, which means it is already producing and selling regulated product rather than waiting on a first approval to generate revenue.

Adding a Phase 3 trial changes the profile. Phase 3 is the final and typically largest stage of human testing before a regulator considers a marketing application. It is designed to confirm whether a treatment works in the intended patient population and to build a safety record at scale. The company has not, in this announcement, disclosed timelines, endpoints, sites or costs beyond the trial's size and design outline — two dosing sessions, up to 100 participants.

Two sessions is a notable detail. MDMA-assisted therapy protocols pair a controlled dose of the drug with structured psychotherapy, and the number of dosing sessions drives both the clinical burden and the cost of delivering treatment in the real world. A two-session protocol, if it holds up, is a shorter course than some regimens studied in the field, which has implications for how many patients a clinic can treat and what a payer would be asked to fund.

Veterans and frontline workers as the study population

The choice of population is deliberate and points at where demand for PTSD treatment is concentrated. Veterans and frontline workers — the group named by the company — face occupational trauma exposure, and both have been the focus of policy attention in Canada around access to mental health treatment. A trial recruiting up to 100 of them is small by the standards of a conventional Phase 3 cardiovascular or oncology program, but psychiatric trials in this area have generally run at that order of magnitude, partly because each participant requires hours of supervised therapy rather than a pill and a follow-up visit.

Health Canada authorization is the gating item. Working with a controlled substance such as MDMA in a clinical setting requires regulatory sign-off on the protocol, on the source of the drug substance, and on the handling of it. For a company that manufactures regulated psychedelic products, clearing that bar is also a signal about the quality systems behind its production.

Where the shares sit

Optimi carries three listings — NASDAQ: OPTH, CSE: OPTI and FSE: 8BN — a structure common among Canadian small-cap life sciences names seeking North American and European retail access. The most recent trade in OPTH, as of 20:00 GMT on Sept. 15, 2026, was at 5.07, up 6.51% from the prior close of 4.76. The session range was 4.53 to 5.20, a wide band that is characteristic of a thinly capitalized clinical-stage name where a single piece of news can move the price several percent in either direction.

That gain came against a broadly weaker tape. The S&P 500 tracker (SPY) closed at $757.39, down 0.46%; the Nasdaq 100 tracker (QQQ) finished at $704.54, down 0.65%; and the Dow tracker (DIA) closed at $521.23, down 0.62%. In other words, Optimi rose while the three main US benchmarks fell — the kind of divergence that usually reflects company-specific flow rather than sector or macro sentiment.

What would confirm the thesis

Investors in this corner of the market have learned to separate announcements of intent from enrolled patients. The items worth tracking from here:

First patient dosed. A Phase 3 that has been authorized is not the same as a Phase 3 that is running. Site activation and recruitment timelines are the practical test.
Funding. Late-stage trials consume cash. Whether the program is financed from manufacturing revenue, partnerships, government or non-profit support, or new equity will shape dilution risk.
Endpoints and readout timing. Neither has been disclosed here. The primary endpoint chosen, and when data are expected, will determine how the market prices the option value.
Manufacturing pull-through. If Optimi supplies the drug product used in its own trial, the program adds internal demand on top of whatever third-party sales it already books.

Investors in this corner of the market have learned to separate announcements of intent from enrolled patients.

The broader psychedelic therapeutics sector has spent several years cycling between regulatory optimism and disappointment, and share prices across the group have been volatile. Optimi's pitch — that it earns revenue from manufacturing while advancing a late-stage asset — is a different shape from the pure development-stage model, and the Phase 3 announcement is the clearest statement yet of that dual strategy. The next disclosures, particularly on cost and timing, will decide whether the market treats it as a manufacturer with an option or as a clinical story with a factory attached.

Key facts

Stock: NASDAQ: OPTH last traded at 5.07, +6.51%, as of 20:00 GMT Sept. 15, 2026
Trial stage: Phase 3, authorized by Health Canada
Design: Two sessions of MDMA-assisted therapy; efficacy and safety endpoints
Enrollment: Up to 100 veterans and frontline workers

Frequently asked questions

What did Optimi Health announce?

On Sept. 16, 2026, Optimi Health Corp. said it plans to expand its clinical program with a Phase 3 trial of MDMA-assisted therapy for post-traumatic stress disorder. The trial is authorized by Health Canada and will evaluate the efficacy and safety of two MDMA-assisted therapy sessions in up to 100 veterans and frontline workers.

Where does Optimi Health trade?

The company carries three listings: NASDAQ: OPTH in the United States, CSE: OPTI on the Canadian Securities Exchange, and FSE: 8BN in Frankfurt. The OPTH line last traded at 5.07, up 6.51% from a prior close of 4.76, as of 20:00 GMT on Sept. 15, 2026, with a session range of 4.53 to 5.20.

What is MDMA-assisted therapy?

It is a treatment approach that pairs a controlled dose of MDMA, given under supervision, with structured psychotherapy sessions. The drug is not taken home or used daily; it is administered during a limited number of monitored sessions. Optimi's planned trial uses two such sessions, which is a shorter course than some protocols studied in the field.

Why does Health Canada authorization matter?

MDMA is a controlled substance, so running a clinical trial with it requires regulatory sign-off on the study protocol, the source and quality of the drug substance, and how the material is handled at sites. Authorization from Health Canada is the gating step that allows the study to proceed and also reflects on the manufacturer's quality systems.

What makes Optimi different from other psychedelic companies?

Optimi describes itself as a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, meaning it already produces and sells product rather than depending solely on a future drug approval. Most peers began as developers and added manufacturing later. The Phase 3 trial moves Optimi from supplier toward owner of clinical evidence.

How did the stock perform against the wider market?

Optimi's NASDAQ line rose 6.51% to 5.07 at its most recent close, while the three main US benchmarks fell. The S&P 500 tracker closed at $757.39, down 0.46%; the Nasdaq 100 tracker at $704.54, down 0.65%; and the Dow tracker at $521.23, down 0.62%, all as of 20:00 GMT on Sept. 15, 2026.

Sources

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder — Financial Post

Photo: RDNE Stock project · Pexels Licence — source